Centessa Pharmaceuticals Appoints One of the World’s Leading Drug Developers, Antoine Yver, M.D., M.Sc., as Chief Medical Officer
Centessa Pharmaceuticals (“Centessa”) today announced that Antoine Yver, M.D., M.Sc., has been appointed as Chief Medical Officer. Dr. Yver is one of the world’s leading drug developers with more than 30 years of global experience in the pharmaceutical industry.
“We are absolutely thrilled to welcome Antoine to our team as CMO,” said Saurabh Saha, M.D., Ph.D., Chief Executive Officer of Centessa. “Antoine is a true industry leader with significant experience and success as a drug developer, having developed some of the most impactful oncology drugs in the world. I look forward to partnering with him as we advance our portfolio of preclinical programs into the clinic and progress our four assets currently in clinical development.”
“I am delighted to be joining Centessa, a differentiated company with a unique operating model,” said Dr. Yver. “Centessa’s asset-centric model exemplifies the very best practices that I have experienced and implemented in the industry. I am honored to be working with such a talented leadership team and exceptional Board and look forward to helping establish this bold new R&D enterprise while we strive to bring important new medicines to patients.”
Dr. Yver brings more than 30 years of global experience in the pharmaceutical industry to Centessa and has played a pivotal role in the development and approvals of 11 different drugs, including Tagrisso®, Lynparza®, and Enhertu®. He led the development of Tagrisso® in 2 years 7 months from first human dose to U.S. approval and its rapid deployment to all other major regions, which was the fastest ever for an anti-cancer drug. Dr. Yver joins the company from Daiichi Sankyo, where he served as Executive Vice President and Global Head, R&D Oncology, and Chair of the Cancer Enterprise. Previously, Dr. Yver was with AstraZeneca, most recently serving as Senior Vice President, Global Medicine Head, Oncology, and Global Medicines Development China Lead. Earlier, he held various clinical development roles at Schering-Plough/Merck, Johnson & Johnson, Aventis Pharmaceuticals, Inc., Rhône-Poulenc Rorer, Inc, Applied Immune Sciences, Inc, and Chugai-RP. Dr. Yver is a pediatric oncologist and holds an M.D. from Université Paris-Saclay.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals Limited is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of programs led by industry-leading teams. Each program is developed by one of ten Centessa subsidiaries and supported by centralized infrastructure and the Centessa management team. For more information, visit www.centessa.com.
Forward Looking Statements
This press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts, which are usually identified by the use of words such as “estimates,” “expects,” “intends,” “anticipates,” “believes,” “may,” “should,” “will,” “plans,” “projects,” “seeks,” and variations of such words or similar expressions. These forward-looking statements, including statements relating to expectations, plans and prospects regarding the clinical development plans and timing, clinical trial designs, clinical and therapeutic potential, and strategy for any of our programs reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the success of clinical trials, regulatory filings, and approvals. These forward-looking statements are based upon the current expectations and beliefs of Centessa’s management team as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Furthermore, Centessa operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Dan Budwick, 1AB
UK/European media enquiries
Optimum Strategic Communications
Mary Clark, Shabnam Bashir
Swiss media enquiries
Cellphone: +41 79 20 75 111
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma24.6.2021 20:00:00 CEST | Press release
Regulatory News: Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain held various leadership positions for the British pharmaceutical group GlaxoSmithKline, most recently as Global President Pharmaceuticals and Vaccines for five years. Prior to that, he worked for 20 years for the U.S. pharmaceutical group Eli Lilly, holding management positions at sites in the US, Europe, Asia and Australia. In recent years, he has contributed his experience as an independent member of the boards of directors of major pharmaceutical, biotech and medical device companies, such as Teva Pharmaceuticals, CSL and Cochlear. He has also acted as an advisor to private equity and venture capital firms focused on the healthcare sector. Abbas Hussain holds a Bachelor of Science in Medicinal and Pharmaceutical Chemistry from Loughborough Institute of Technology (UK), graduated from Duke Unive
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System24.6.2021 19:17:00 CEST | Press release
Invivoscribe, a global leader in precision diagnostics, has announced the launch of an Immune Biomarker Discovery grant program, focused on supporting development, validation and deployment of novel applications for use of their distributed LymphoTrack® NGS products and bioinformatics software. Massively parallel sequencing coupled with reagents targeting the immune receptor loci have accelerated our understanding of the immune response and immunology related disease processes. The availability of distributed RUO LymphoTrack tests and bioinformatics have eliminated a majority of the barriers of a service model approach, and have accelerated the ability to identify, track and monitor biomarkers associated with hematologic malignancies. These products are also being deployed worldwide to track the manufacture and treatment of immunotherapy, such as CAR T-cell therapies, and provide a comprehensive way to track a subject’s immune response to disease processes and to vaccines. In conversat
Nucleai and Merck KGaA Darmstadt, Germany Launch Translational Medicine Collaboration Utilizing Nucleai’s AI-Powered Biomarker Platform24.6.2021 17:17:00 CEST | Press release
Nucleai (www.nucleaimd.com), a precision medicine company using AI-powered image analysis technology to support novel pathology-based biomarker development, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that they have entered into a long-term collaboration to leverage Nucleai's image analysis and biomarker discovery platform for several Merck KGaA, Darmstadt, Germany clinical stage oncology assets. As part of the collaboration, Merck KGaA, Darmstadt, Germany will leverage Nucleai’s platform for exploratory research, with the potential to further develop identified pathology-based biomarkers as companion diagnostics. The collaboration will further utilize Nucleai’s technology to expand onto Merck KGaA, Darmstadt, Germany’s analysis capabilities, enabling faster turnaround time and scale for future studies. Nucleai's platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system's spati
Andersen Global Enters Collaboration Agreement With One of Lesotho’s Largest Law Firms24.6.2021 15:30:00 CEST | Press release
Andersen Global extends its African presence through a Collaboration Agreement with one of Lesotho’s largest law firms, Webber Newdigate Attorneys, enhancing the organization’s coverage in the southern region of the continent. Webber Newdigate Attorneys, established in 1978, is located in the capital city, Maseru. Recognized by Chambers Global and consistently awarded by PMR Africa, the full-service firm provides legal services to both local and international clients including individuals, companies, multinationals, government authorities, banks and parastatal organizations. The firm also covers a range of industries with capabilities in tax, real estate, employment law, corporate and commercial, litigation, banking and finance, mining and resources, immigration and family law. “For more than 40 years, our team has consistently delivered high-quality solutions to our clients, including those of an intricate nature,” said Partner Alex de Wet. “Andersen Global’s culture echoes our firm’s
New Outseer Fraud & Payments Report Confirms Massive Increase in Brand Abuse Cyber Attacks, Jumping 158% From Q1 202024.6.2021 15:00:00 CEST | Press release
Outseer has published its latest quarterly fraud and payments report, uncovering a significant spike in brand abuse attacks and a continued shift to more precise payment authentication methods. The Q2 installment of the report features insights from January through March of 2021 as captured through the Outseer Global Data Network, and collected while authenticating consumer transactions and investigating threats on behalf of Outseer customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005352/en/ (Graphic: Business Wire) According to the report, Brand Abuse attacks impersonating companies through social media and published content now represents the majority of fraud attacks, growing from 27% in Q4 2020 to 68% in Q1 2021. This dramatic shift is attributed to the increased use of digital platforms including social media, web publishing, and cloud-based collaboration tools during the pandemic – all fertile hunting gr
IATA Strengthens Operational Scalability By Switching to Rimini Street for Integrated Support and Application Management Services for its SAP Applications24.6.2021 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that International Air Transport Association (IATA), the leading commercial aviation trade association headquartered in Montreal, Canada, has switched to Rimini Street Support and Application Management Services (AMS) for its SAP ECC 6.0 and Business Objects applications. With the commercial aviation sector heavily affected by the COVID-19 pandemic, IATA made strategic business decisions to navigate the crisis, including outsourcing key elements of its IT service delivery to reduce operating costs. As a result of switching to Rimini Street, the organization now benefits from a unified support solution that integrates application support and managed services, enabling IATA to meet business demand in a post-pandemic recovery. This press release features multimedia. View t
XPeng Inc. Launches Hong Kong Public Offering24.6.2021 14:59:00 CEST | Press release
XPeng Inc. (“XPeng” or the “Company”, NYSE: XPEV), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced the launch of its Hong Kong public offering (the “Hong Kong Public Offering”), which forms part of the global offering (the “Global Offering”) of 85,000,000 new Class A ordinary shares of the Company (the “Offer Shares”) and listing of its Class A ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) under the stock code “9868” (the “Proposed Listing”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005620/en/ XPeng P7 Wing edition (Photo: Business Wire) The Company’s American depositary shares (the “ADSs”), each representing two Class A ordinary shares of the Company, will continue to be listed and traded on the New York Stock Exchange (“NYSE”). The Proposed Listing is a dual-primary listing of the Class A ordinary shares of the Compan